SMC PHARMA SERVICES LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +1,411.3%

  £138,972 → £2,100,244

• Cash

  +127.5%

  £332,371 → £755,993

  highest in 5 filed years

• Net assets

  -34.4%

  -£26,011,490 → -£34,967,782

  lowest in 5 filed years

• Employees

  -56.9%

  65 → 28

• Operating profit

  +53.1%

  -£15,999,911 → -£7,509,057

• Profit before tax

  +48.2%

  -£17,118,443 → -£8,873,953

• Wages

  -47.8%

  £4,675,432 → £2,439,999

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. SMC PHARMA SERVICES LTD 2024-04-23 → present
2. CAMBRIDGE PHARMA LIMITED 2016-10-26 → 2024-04-23

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Price Bailey LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the basis that the Group is a going concern. In reaching this decision, the directors have considered projections of the cash flows of the Group for the next twelve months covering the existing commitments of the Group together with additional investment required to develop autoinjector technologies and that required to ensure the business completes the fit-out of its leasehold facility that will deliver pharmaceutical development and contract manufacturing services for small batch fill finish. The cash flows indicate that the Group may need additional finance during 2025 and 2026, which will be provided via a related Company, Scientific Molding Corporation Ltd. At the balance sheet date, as highlighted in Note 20, the Group had borrowed £43,521,366 via loan notes with Scientific Molding Corporation Ltd, over a 10-year term expiring 1 December 2031. Since the year end, in the first half of 2025, Scientific Molding Corporation Ltd have provided additional funding as required. Scientific Molding Corporation Ltd have confirmed they have sufficient funds to provide such further funding and their willingness to provide their continued financial support for a period of 12 months from the date of approval of these financial statements.”

Group structure

1. SMC PHARMA SERVICES LTD · parent
   1. Oval Medical Technologies Limited 100% · United Kingdom · R&D to develop its autoinjector platform technologies

Significant events

• “During the year, the Group continued the fit out of its leasehold facility that will deliver a pharmaceutical development and contract manufacturing service for small batch fill finish.”
• “The Group's employee numbers decreased to an average of 28 in 2024, down from an average of 65 in the 2023 period following a restructure of the Group's operations.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.